Financhill
Sell
14

RSLS Quote, Financials, Valuation and Earnings

Last price:
$0.30
Seasonality move :
-20.69%
Day range:
$0.34 - $0.38
52-week range:
$0.30 - $29.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.02x
P/B ratio:
0.18x
Volume:
2M
Avg. volume:
24.4M
1-year change:
-96.12%
Market cap:
$4.1M
Revenue:
$8M
EPS (TTM):
-$16.01

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
RSLS
Reshape Lifesciences
$2.1M -$9.28 -- -- --
AXGN
Axogen
$48.3M $0.02 16.84% -76% $25.71
ELMD
Electromed
$15.8M -- 13.91% -- $37.00
IRIX
IRIDEX
$12.8M -$0.12 -2.72% -18.18% --
MYO
Myomo
$9.2M -$0.08 145.61% -24% $9.25
STXS
Stereotaxis
$6.9M -$0.07 -0.07% -20.83% $4.50
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
RSLS
Reshape Lifesciences
$0.36 -- $4.1M -- $0.00 0% 0.02x
AXGN
Axogen
$15.58 $25.71 $690.9M -- $0.00 0% 3.68x
ELMD
Electromed
$22.67 $37.00 $194M 30.23x $0.00 0% 3.40x
IRIX
IRIDEX
$1.03 -- $17.1M -- $0.00 0% 0.35x
MYO
Myomo
$4.27 $9.25 $146.8M -- $0.00 0% 4.95x
STXS
Stereotaxis
$1.79 $4.50 $153.9M -- $0.00 0% 5.66x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
RSLS
Reshape Lifesciences
-- 5.292 -- 0.52x
AXGN
Axogen
31.37% 1.669 6.53% 1.88x
ELMD
Electromed
-- 1.939 -- 4.68x
IRIX
IRIDEX
51.25% 1.717 9.47% 0.73x
MYO
Myomo
-- 2.090 -- 2.82x
STXS
Stereotaxis
-- 1.683 -- 0.74x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
RSLS
Reshape Lifesciences
$1.4M -$1.8M -187.93% -187.93% -76.83% -$311K
AXGN
Axogen
$37.6M $2M -6.89% -10.21% 4.56% $7.9M
ELMD
Electromed
$12.6M $2.5M 15.91% 15.91% 15.64% $2.9M
IRIX
IRIDEX
$4.3M -$1.9M -146.36% -157.91% -16.15% -$3.1M
MYO
Myomo
$8.6M -$245.3K -48.64% -48.64% -2.03% $2.5M
STXS
Stereotaxis
$3.2M -$7.6M -139.2% -139.2% -120.3% $1.3M

Reshape Lifesciences vs. Competitors

  • Which has Higher Returns RSLS or AXGN?

    Axogen has a net margin of -68.98% compared to Reshape Lifesciences's net margin of 0.91%. Reshape Lifesciences's return on equity of -187.93% beat Axogen's return on equity of -10.21%.

    Company Gross Margin Earnings Per Share Invested Capital
    RSLS
    Reshape Lifesciences
    62.78% -$3.11 $1.5M
    AXGN
    Axogen
    76.06% $0.01 $151.4M
  • What do Analysts Say About RSLS or AXGN?

    Reshape Lifesciences has a consensus price target of --, signalling upside risk potential of 15873.54%. On the other hand Axogen has an analysts' consensus of $25.71 which suggests that it could grow by 65.05%. Given that Reshape Lifesciences has higher upside potential than Axogen, analysts believe Reshape Lifesciences is more attractive than Axogen.

    Company Buy Ratings Hold Ratings Sell Ratings
    RSLS
    Reshape Lifesciences
    0 0 0
    AXGN
    Axogen
    5 0 0
  • Is RSLS or AXGN More Risky?

    Reshape Lifesciences has a beta of 1.592, which suggesting that the stock is 59.165% more volatile than S&P 500. In comparison Axogen has a beta of 0.995, suggesting its less volatile than the S&P 500 by 0.462%.

  • Which is a Better Dividend Stock RSLS or AXGN?

    Reshape Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Reshape Lifesciences pays -- of its earnings as a dividend. Axogen pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RSLS or AXGN?

    Reshape Lifesciences quarterly revenues are $2.3M, which are smaller than Axogen quarterly revenues of $49.4M. Reshape Lifesciences's net income of -$1.6M is lower than Axogen's net income of $450K. Notably, Reshape Lifesciences's price-to-earnings ratio is -- while Axogen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Reshape Lifesciences is 0.02x versus 3.68x for Axogen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RSLS
    Reshape Lifesciences
    0.02x -- $2.3M -$1.6M
    AXGN
    Axogen
    3.68x -- $49.4M $450K
  • Which has Higher Returns RSLS or ELMD?

    Electromed has a net margin of -68.98% compared to Reshape Lifesciences's net margin of 12.11%. Reshape Lifesciences's return on equity of -187.93% beat Electromed's return on equity of 15.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    RSLS
    Reshape Lifesciences
    62.78% -$3.11 $1.5M
    ELMD
    Electromed
    77.68% $0.22 $43.6M
  • What do Analysts Say About RSLS or ELMD?

    Reshape Lifesciences has a consensus price target of --, signalling upside risk potential of 15873.54%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 63.21%. Given that Reshape Lifesciences has higher upside potential than Electromed, analysts believe Reshape Lifesciences is more attractive than Electromed.

    Company Buy Ratings Hold Ratings Sell Ratings
    RSLS
    Reshape Lifesciences
    0 0 0
    ELMD
    Electromed
    2 0 0
  • Is RSLS or ELMD More Risky?

    Reshape Lifesciences has a beta of 1.592, which suggesting that the stock is 59.165% more volatile than S&P 500. In comparison Electromed has a beta of 0.594, suggesting its less volatile than the S&P 500 by 40.575%.

  • Which is a Better Dividend Stock RSLS or ELMD?

    Reshape Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Reshape Lifesciences pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RSLS or ELMD?

    Reshape Lifesciences quarterly revenues are $2.3M, which are smaller than Electromed quarterly revenues of $16.3M. Reshape Lifesciences's net income of -$1.6M is lower than Electromed's net income of $2M. Notably, Reshape Lifesciences's price-to-earnings ratio is -- while Electromed's PE ratio is 30.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Reshape Lifesciences is 0.02x versus 3.40x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RSLS
    Reshape Lifesciences
    0.02x -- $2.3M -$1.6M
    ELMD
    Electromed
    3.40x 30.23x $16.3M $2M
  • Which has Higher Returns RSLS or IRIX?

    IRIDEX has a net margin of -68.98% compared to Reshape Lifesciences's net margin of -16.69%. Reshape Lifesciences's return on equity of -187.93% beat IRIDEX's return on equity of -157.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    RSLS
    Reshape Lifesciences
    62.78% -$3.11 $1.5M
    IRIX
    IRIDEX
    37.33% -$0.12 $5.4M
  • What do Analysts Say About RSLS or IRIX?

    Reshape Lifesciences has a consensus price target of --, signalling upside risk potential of 15873.54%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 94.18%. Given that Reshape Lifesciences has higher upside potential than IRIDEX, analysts believe Reshape Lifesciences is more attractive than IRIDEX.

    Company Buy Ratings Hold Ratings Sell Ratings
    RSLS
    Reshape Lifesciences
    0 0 0
    IRIX
    IRIDEX
    0 0 0
  • Is RSLS or IRIX More Risky?

    Reshape Lifesciences has a beta of 1.592, which suggesting that the stock is 59.165% more volatile than S&P 500. In comparison IRIDEX has a beta of 0.737, suggesting its less volatile than the S&P 500 by 26.316%.

  • Which is a Better Dividend Stock RSLS or IRIX?

    Reshape Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Reshape Lifesciences pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RSLS or IRIX?

    Reshape Lifesciences quarterly revenues are $2.3M, which are smaller than IRIDEX quarterly revenues of $11.6M. Reshape Lifesciences's net income of -$1.6M is higher than IRIDEX's net income of -$1.9M. Notably, Reshape Lifesciences's price-to-earnings ratio is -- while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Reshape Lifesciences is 0.02x versus 0.35x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RSLS
    Reshape Lifesciences
    0.02x -- $2.3M -$1.6M
    IRIX
    IRIDEX
    0.35x -- $11.6M -$1.9M
  • Which has Higher Returns RSLS or MYO?

    Myomo has a net margin of -68.98% compared to Reshape Lifesciences's net margin of -2.16%. Reshape Lifesciences's return on equity of -187.93% beat Myomo's return on equity of -48.64%.

    Company Gross Margin Earnings Per Share Invested Capital
    RSLS
    Reshape Lifesciences
    62.78% -$3.11 $1.5M
    MYO
    Myomo
    71.39% -$0.01 $24.7M
  • What do Analysts Say About RSLS or MYO?

    Reshape Lifesciences has a consensus price target of --, signalling upside risk potential of 15873.54%. On the other hand Myomo has an analysts' consensus of $9.25 which suggests that it could grow by 116.63%. Given that Reshape Lifesciences has higher upside potential than Myomo, analysts believe Reshape Lifesciences is more attractive than Myomo.

    Company Buy Ratings Hold Ratings Sell Ratings
    RSLS
    Reshape Lifesciences
    0 0 0
    MYO
    Myomo
    3 0 0
  • Is RSLS or MYO More Risky?

    Reshape Lifesciences has a beta of 1.592, which suggesting that the stock is 59.165% more volatile than S&P 500. In comparison Myomo has a beta of 1.548, suggesting its more volatile than the S&P 500 by 54.752%.

  • Which is a Better Dividend Stock RSLS or MYO?

    Reshape Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Reshape Lifesciences pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RSLS or MYO?

    Reshape Lifesciences quarterly revenues are $2.3M, which are smaller than Myomo quarterly revenues of $12.1M. Reshape Lifesciences's net income of -$1.6M is lower than Myomo's net income of -$260.1K. Notably, Reshape Lifesciences's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Reshape Lifesciences is 0.02x versus 4.95x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RSLS
    Reshape Lifesciences
    0.02x -- $2.3M -$1.6M
    MYO
    Myomo
    4.95x -- $12.1M -$260.1K
  • Which has Higher Returns RSLS or STXS?

    Stereotaxis has a net margin of -68.98% compared to Reshape Lifesciences's net margin of -118.53%. Reshape Lifesciences's return on equity of -187.93% beat Stereotaxis's return on equity of -139.2%.

    Company Gross Margin Earnings Per Share Invested Capital
    RSLS
    Reshape Lifesciences
    62.78% -$3.11 $1.5M
    STXS
    Stereotaxis
    50.73% -$0.09 $11.4M
  • What do Analysts Say About RSLS or STXS?

    Reshape Lifesciences has a consensus price target of --, signalling upside risk potential of 15873.54%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 151.4%. Given that Reshape Lifesciences has higher upside potential than Stereotaxis, analysts believe Reshape Lifesciences is more attractive than Stereotaxis.

    Company Buy Ratings Hold Ratings Sell Ratings
    RSLS
    Reshape Lifesciences
    0 0 0
    STXS
    Stereotaxis
    2 0 0
  • Is RSLS or STXS More Risky?

    Reshape Lifesciences has a beta of 1.592, which suggesting that the stock is 59.165% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.223%.

  • Which is a Better Dividend Stock RSLS or STXS?

    Reshape Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Reshape Lifesciences pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RSLS or STXS?

    Reshape Lifesciences quarterly revenues are $2.3M, which are smaller than Stereotaxis quarterly revenues of $6.3M. Reshape Lifesciences's net income of -$1.6M is higher than Stereotaxis's net income of -$7.5M. Notably, Reshape Lifesciences's price-to-earnings ratio is -- while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Reshape Lifesciences is 0.02x versus 5.66x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RSLS
    Reshape Lifesciences
    0.02x -- $2.3M -$1.6M
    STXS
    Stereotaxis
    5.66x -- $6.3M -$7.5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Micron a Good Stock to Buy Now?
Is Micron a Good Stock to Buy Now?

Like most of its peers in the semiconductor industry, Micron…

Is Uber Finally on the Path to Consistent Profitability?
Is Uber Finally on the Path to Consistent Profitability?

After posting massive losses quarter after quarter for years, Uber…

How High Will MSTY Go By 2030?
How High Will MSTY Go By 2030?

YieldMax’s MSTR Option Income Strategy ETF (MSTY) is a high-yield…

Stock Ideas

Sell
48
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Sell
46
Is MSFT Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 31x

Sell
42
Is NVDA Stock a Buy?

Market Cap: $2.5T
P/E Ratio: 36x

Alerts

Buy
91
TORXF alert for Apr 17

Torex Gold Resources [TORXF] is down 2.46% over the past day.

Sell
25
BULZ alert for Apr 17

MicroSectors Solactive FANG & Innov 3X Levd ETN [BULZ] is down 1.92% over the past day.

Sell
44
VIST alert for Apr 17

Vista Energy SAB de CV [VIST] is up 7.2% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock